These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9887400)

  • 1. [The cardiotoxicity of anthracyclines administered in childhood].
    Iarussi D; Indolfi P; Ratti G; Martiniello AR; Iacono A
    G Ital Cardiol; 1998 Dec; 28(12):1431-40. PubMed ID: 9887400
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiotoxicity of anthracycline].
    Wojtukiewicz MZ; Omyła J; Kozłowski L; Szynaka B
    Postepy Hig Med Dosw; 2000; 54(4):467-85. PubMed ID: 11016267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiotoxicity in anthracycline chemotherapy: significance of infusion durations. Analysis of a Cochrane review].
    Appel JM; Rybjerg M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3105-7. PubMed ID: 17877960
    [No Abstract]   [Full Text] [Related]  

  • 4. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic possibilities of late cardiotoxic sequelae of chemotherapy with anthracyclines].
    Elbl L; Hrstková H; Chaloupka V; Novotný J
    Vnitr Lek; 2002 Oct; 48(10):981-8. PubMed ID: 16737150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of anthracycline-induced cardiotoxicity.
    Meinardi MT; van der Graaf WT; van Veldhuisen DJ; Gietema JA; de Vries EG; Sleijfer DT
    Cancer Treat Rev; 1999 Aug; 25(4):237-47. PubMed ID: 10448132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience.
    Sallan SE; Clavell LA
    Semin Oncol; 1984 Dec; 11(4 Suppl 3):19-21. PubMed ID: 6594762
    [No Abstract]   [Full Text] [Related]  

  • 8. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracyclines.
    Gianni L; Grasselli G; Cresta S; Locatelli A; Viganò L; Minotti G
    Cancer Chemother Biol Response Modif; 2003; 21():29-40. PubMed ID: 15338739
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dexrazoxane and cardiotoxicity in repeatedly treated patients].
    Trnĕný M
    Vnitr Lek; 2004 Jun; 50(6):417-8. PubMed ID: 15346632
    [No Abstract]   [Full Text] [Related]  

  • 12. The anthracycline cardiotoxicity debate.
    Finlay J; Meadows AT
    Pediatrics; 1994 Nov; 94(5):780-1; author reply 781-2. PubMed ID: 7936925
    [No Abstract]   [Full Text] [Related]  

  • 13. Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing's sarcoma.
    Perel RD; Slaughter RE; Strugnell WE
    J Cardiovasc Magn Reson; 2006; 8(6):789-91. PubMed ID: 17060100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline cardiotoxicity in childhood.
    Ruggiero A; Ridola V; Puma N; Molinari F; Coccia P; De Rosa G; Riccardi R
    Pediatr Hematol Oncol; 2008 Jun; 25(4):261-81. PubMed ID: 18484471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac safety, risk management, and oncology drug development.
    Fingert HJ; Varterasian ML
    Clin Cancer Res; 2006 Jun; 12(12):3646-7. PubMed ID: 16778090
    [No Abstract]   [Full Text] [Related]  

  • 17. Anthracyclines: cardiotoxicity and its prevention.
    Hale JP; Lewis IJ
    Arch Dis Child; 1994 Nov; 71(5):457-62. PubMed ID: 7826122
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
    Conklin KA
    Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline cardiotoxicity: one size does not fit all!
    Hershman DL; Neugut AI
    J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.